Chemosensory assessment and impact on quality of life in neurosensorial cluster of the post COVID 19 syndrome
Elisa Gentilotti,Anna Gorska,Maria Paola Cecchini,Massimo Mirandola,Marco Meroi,Pasquale De Nardo,Andrea Sartori,Chiara Konishi De Toffoli,Samir Kumar-Singh,Gianluigi Zanusso,Salvatore Monaco,Evelina Tacconelli,the ORCHESTRA-UNIVR Study Group,Mariana Nunes Pinho Guedes,Gaia Maccarrone,Lorenzo Maria Canziani,Ruth Joanna Davies,Stefania Vitali,Giorgia Tomassini,Benedetta Barana,Maria Diletta Pezzani,Marcella Sibani,Fulvia Mazzaferri,Alessia Savoldi,Elda Righi,Giorgia Franchina,Maria Mongardi,Simona Sorbello,Miriam Emiliani,Raffaella Cordioli,Alessio Esposito,Concetta Sciammarella,Giulia Rosini,Chiara Perlini,Filippo Cioli Puviani,Daniele Fasan,Alessandro Visentin,Salvatore Hermes Dall'O',Chiara Zanchi,Maddalena Armellini,Enrico Gibbin,Laura Rovigo,Lorenzo Tavernaro,Matilde Rocchi,Rebecca Scardellato,Francesco Luca,Alessandro Castelli,Federico Lattanzi,Carmine Cutone,Anna Giulia Salvadori,Lucia Bonato,Lidia Del Piccolo,Maddalena Marcanti,Marco Pattaro Zonta,Deborah Calì,Anna Mason,Cinzia Perlini,Angelina Konnova,Akshita Gupta,Mathias Smet,An Hotterbeekx,Surbhi Malhotra-Kumar,Gabriella Scipione,Elisa Rossi,Salvatore Cataudella,Chiara Della Casa,Balasubramanian Chandramouli,Silvia Gioiosa,Juan Mata Naranjo,Maurizio Ortali,Riccardo Cecchetto,Davide Gibellini
DOI: https://doi.org/10.1038/s41598-024-71475-3
IF: 4.6
2024-09-11
Scientific Reports
Abstract:COVID-19 pandemic brought chemosensory impairment to the forefront of medicine, revealing gaps in the knowledge of pathophysiological mechanisms, true prevalence and preventive/therapeutic alternatives. This is a sub-study of the ORCHESTRA cohort focusing on post-COVID-19 chemosensory symptoms. Risk factors for neurosensorial cluster of post-COVID-19 syndrome (NSc-PCS) were assessed through multivariable analysis. Psychophysical validated tests were applied on a sub-population of 50 patients. Qualitative chemosensory symptoms as well as nasal and oral chemesthesis were evaluated through anamnestic interview and the quality of life through the SF-36 questionnaire. Chemosensory symptoms evolution and olfactory training's outcome were assessed through phone-call interviews. Out of 1187 patients (female, N = 630), 550 (47%) presented NSc-PCS, with a lower risk for older age and monoclonal antibodies treatment, and a higher risk in females (p < 0.001). Out of the 50 patients evaluated with psychophysical tests, 66% showed smell reduction with a qualitative alteration in 50% of hyposmic and 35% of normosmic patients. Hypogeusia was present in 14 (28%) of the patients assessed, with 56% showing a qualitative alteration; 53% of normogeusic patients presented qualitative disorders. NSc-PCS has a complex, fluctuating, multifaceted presentation. Quantifying and characterizing COVID-19-related chemosensory impairment is key to understand underlying mechanisms and to develop preventive and therapeutic treatment.
multidisciplinary sciences